Luis Fayad
Overview
Explore the profile of Luis Fayad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
118
Citations
4191
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gaulin C, Jain P, Nair R, Iyer S, Lee H, Fayad L, et al.
Leuk Lymphoma
. 2025 Jan;
1-5.
PMID: 39838574
No abstract available.
2.
Fang P, Noticewala S, Wu S, Gunther J, Ludmir E, Medeiros L, et al.
Adv Radiat Oncol
. 2024 Nov;
9(12):101650.
PMID: 39553398
Purpose: Extranodal NK/T-cell lymphoma (ENKTCL) is rare in the Western Hemisphere and is commonly treated with combined modality therapy (CMT). Methods And Materials: We retrospectively reviewed 35 patients treated with...
3.
Gunther J, Xu J, Bhutani M, Strati P, Fang P, Wu S, et al.
Lancet Haematol
. 2024 Jun;
11(7):e521-e529.
PMID: 38843856
Background: Given the favourable prognosis of patients with gastric mucosa-associated lymphoid tissue (MALT) lymphoma, treatment-related toxicity should be minimised. We aimed to evaluate the efficacy of 4 Gy radiotherapy given...
4.
Lionel A, Gurumurthi A, Fetooh A, Eldaya R, Ahmed S, Iyer S, et al.
Leuk Lymphoma
. 2024 Jan;
65(5):669-673.
PMID: 38248629
No abstract available.
5.
Ramchandren R, Johnson P, Ghosh N, Ruan J, Ardeshna K, Johnson R, et al.
EClinicalMedicine
. 2023 Jan;
56:101779.
PMID: 36618900
Background: This phase 1b/2 PCYC-1123-CA study evaluated efficacy and safety of the combination of ibrutinib, lenalidomide, and rituximab (iR regimen) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) ineligible...
6.
Cherng H, Alig S, Oki Y, Nastoupil L, Fayad L, Neelapu S, et al.
Blood Adv
. 2022 Nov;
7(7):1137-1145.
PMID: 36375046
Diffuse large B-cell lymphoma (DLBCL) can be cured with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); however, one-third of patients experience refractory or relapsed disease. Studies comparing R-CHOP with modified...
7.
Cherng H, Xu G, Feng L, Steiner R, Fayad L, Strati P, et al.
Br J Haematol
. 2022 Sep;
200(1):35-44.
PMID: 36068929
Salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) is a potentially curative treatment for patients with relapsed or refractory large B-cell lymphoma (rrLBCL) with chemosensitive disease....
8.
Westin J, Davis R, Feng L, Hagemeister F, Steiner R, Lee H, et al.
J Clin Oncol
. 2022 Aug;
41(4):745-755.
PMID: 35952327
Purpose: Chemoimmunotherapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) is largely unchanged for decades. Both preclinical models and clinical data suggest the combination of lenalidomide and ibrutinib...
9.
Han G, Deng Q, Marques-Piubelli M, Dai E, Dang M, Ma M, et al.
Blood Cancer Discov
. 2022 Jun;
3(5):428-443.
PMID: 35687817
Significance: We have characterized the FL-infiltrating T cells, identified cytotoxic CD4 T cells as an important component that is associated with tumor cell-intrinsic characteristics, and identified sets of targetable immune...
10.
Saini N, Swoboda D, Greenbaum U, Ma J, Patel R, Devashish K, et al.
Blood Cancer Discov
. 2022 May;
3(5):385-393.
PMID: 35533245
Significance: Our study reveals that CH mutations, especially those associated with inflammation (DNMT3A, TET2, and ASXL1), are associated with severe-grade neurotoxicities in lymphoma patients receiving anti-CD19 CAR T-cell therapy. Further...